Skip to content
WealthTicker
Back to screener
EquitySectoral/ ThematicDirectVery High
Nippon India logo

Nippon India Pharma Fund

Nippon India Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV
₹660.72
+0.44% 1D
as of 19 Nov 2026

Performance

+14.05%absolute
52-week rangePrev NAV ₹657.80
Latest ₹660.72
Low ₹539.2798th percentile of its 52-week rangeHigh ₹663.12

Scorecard

Not rated
How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. Not rated — too few comparable Equity funds (same plan and option) to rank against yet.

Performance—

Not enough Sectoral/ Thematic peers to rank yet

Risk—

Volatility 13.1% (no category average yet)

Cost—

1.0% expense (no category average yet)

ConsistencyHigh

99% of rolling 3Y windows were positive

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

  • Consistent — positive in 99% of rolling 3-year windows

Concerns

No significant concerns identified.

Key Metrics

0.99%
Direct 0.99% · Regular 1.85%
Category —
41.81
Category —
0.86
Category —

Scheme Info

Definitions
Plan
Direct
None
1.00%
0.005%
SIP Inv.
Allowed
₹100
₹5,000
BSE Healthcare TRI
05 Jun 2004

Period returns (<1Y, absolute — not annualized)

Definitions
+10.46%
+2.99%
+7.32%
+15.95%

Annualized returns (≥1Y — CAGR)

Definitions
+14.05%
+17.81%
+15.23%
+16.53%
+17.53%
Advanced metrics — risk and benchmark ratios

Fund vs category average (Sectoral/ Thematic)

PeriodFundCategory avg.Diff
1M abs+10.46%——
3M abs+2.99%——
6M abs+7.32%——
1Y CAGR+14.05%——
3Y CAGR+17.81%——
5Y CAGR+15.23%——

Category average across peers in Sectoral/ Thematic, same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Period
Invested
₹6.00L
Current value
₹9.33L
Absolute
+55.47%
XIRR
+18.25%
Value vs. invested
ValueInvested

60 monthly installments of ₹10,000 into Nippon India Pharma Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

Calendar-year returns

What the fund actually returned in each year, not the smoothed average.

YearFundNifty Healthcare TRIDiff
2026part+15.95%+19.00%-3.05%
2025-2.46%-1.53%-0.93%
2024+35.26%+41.34%-6.08%
2023+40.36%+33.89%+6.47%
2022-9.06%-10.17%+1.11%
2021+25.12%+19.01%+6.11%
2020+67.92%——
2019+2.51%——
2018+4.56%——
2017+8.57%——

January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.

History points
3,414
Expense ratio
0.99%
AUM
₹9,272Cr
Portfolio turnover
18%
Exit load
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Portfolio, AUM & scheme details shown from another plan of this scheme (same underlying portfolio).
P/E ratio
41.8
P/B ratio
7.7
Avg market cap
₹1,25,750Cr
P/E & P/B are portfolio-weighted harmonic means across 30 of 37 equity holdings (91% of the portfolio); loss-making companies are excluded.

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)
20%
Held under 1 year

Flat, on the whole gain

Long-term (LTCG)
12.5%
Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Asset allocation

As on 31 Oct 2026 · AMC disclosure
  • Equity99.62%
  • Cash & Equivalents0.38%

Fund size over time

Quarterly average AUM · AMFI
₹9,272Cr
July - September 2026
+14%
since January - March 2026
+₹298.90Cr
est. net flow, last quarter

At or near its largest, ₹9,272Cr in July - September 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.

Net flow is an estimate: AMFI publishes a quarterly average AUM, not a closing balance, and it covers every plan and option of this scheme together, so it is a read on direction and rough size rather than a cash-flow statement.

Nippon India Mutual Fund logo

AMC Profile

Nippon India Mutual Fund is managed by Nippon Life India Asset Management, which took control of the former Reliance Mutual Fund in 2019 when Nippon Life of Japan bought out the Reliance Capital stake. It is among India's largest fund houses by assets and is best known for its small- and mid-cap franchise.

Launched
29 Jun 1995
Total AUM
₹7,87,053Cr+4.7% QoQ
Avg AUM · July - September 2026

Fund Managers

SBSailesh Raj BhanManaging since 01 Jun 2004
Role

CIO – Equity Investments

Education

MBA(Finance) CFA (ICFAI)

Experience

Over 29 years experience in Equity Securities research and analysis February 2014 to till date Deputy CIO - Equity Investments, NAM India, – managing various Schemes of NIMF. May 2010 to January 2014 Sr. Fund Manager - Investment Equity Oct 2006 to April 2009 Fund Manager -Equity Nov 2003 – Sept 2006 NAM India - Senior Analyst 2001-2003 Emkay Share & Stock Broker Pvt. Ltd Head – Research 1996-2001 Shah & Sequeira Invst. Pvt. Ltd Analyst - Equity research 1995-1996 ICFAI- Securities Research Center Analyst - Equity Research

All schemes Sailesh Raj Bhan runs →

Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Benchmark and dealing terms from it and this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

Frequently asked questions

What is the NAV of Nippon India Pharma Fund?

As of 19 Nov 2026, the NAV of Nippon India Pharma Fund is ₹660.72 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has Nippon India Pharma Fund delivered?

Nippon India Pharma Fund has returned +14.05% over 1 year, +17.81% per year over 3 years, +15.23% per year over 5 years and +17.53% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of Nippon India Pharma Fund?

Nippon India Pharma Fund charges an expense ratio of 0.99% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of Nippon India Pharma Fund?

Nippon India Pharma Fund's largest holdings are Sun Pharmaceutical Industries Limited (11.6%), Divi's Laboratories Limited (6.7%), Cipla Limited (6.2%), Lupin Limited (6.2%) and Dr. Reddy's Laboratories Limited (6.1%). Holdings are disclosed monthly and change over time.

How risky is Nippon India Pharma Fund?

Nippon India Pharma Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 13.1% and its worst peak-to-trough fall in our sample was 24.0%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What does the Sharpe ratio of 0.86 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Nippon India Pharma Fund's 0.86 means it has rewarded its volatility with excess return. Higher is better.

What is the benchmark of Nippon India Pharma Fund?

Nippon India Pharma Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.

Who manages Nippon India Pharma Fund?

Nippon India Pharma Fund is managed by Sailesh Raj Bhan at Nippon India.

When was Nippon India Pharma Fund launched, and what is its objective?

Nippon India Pharma Fund was launched on 05 Jun 2004. its stated objective is: The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.

How is Nippon India Pharma Fund taxed?

Nippon India Pharma Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.